Paradigm’s iPPS Osteoarthritis Data at OARSI Strengthen Case for Phase 3 Program

The latest update is out from Paradigm Biopharmaceuticals ( (AU:PAR) ).

Paradigm Biopharmaceuticals reported new mechanistic and clinical insights into its injectable pentosan polysulfate sodium (iPPS) for knee osteoarthritis, presented by Chief Medical Officer Dr Donna Skerrett at the 2026 Osteoarthritis Research Society International Congress in Florida. The data, drawn from the 61-patient PARA_OA_008 Phase 2 trial and published in Arthritis Research & Therapy, showed broad biomarker modulation across cartilage, inflammation and pain pathways in patients with moderate to severe radiographic disease.

The biomarker profiling across synovial fluid, serum and urine indicated reductions in cartilage degradation markers such as COMP, ARGS, C2C and CTX-II, alongside early decreases in inflammatory and pain mediators including TNF-α and β-NGF by Day 56, and increased levels of TIMP-1, which inhibits cartilage breakdown. Temporal analysis highlighted an early impact on inflammation and pain followed by sustained effects on cartilage turnover and extracellular matrix markers, with key signals including approximately 50–74% reductions in synovial ARGS versus placebo at Day 56.

Correlation analyses linked these biomarker changes with improvements in WOMAC pain, stiffness and function, as well as Patient Global Impression of Change, supporting a mechanistic connection between biological activity and observed clinical benefit, particularly in the twice-weekly dosing group. Although the Phase 2 study was not powered for definitive clinical endpoints, the findings bolster Paradigm’s ongoing PARA_OA_012 Phase 3 program, informing dose selection and reinforcing a strategic emphasis on targeting cartilage-related disease pathways in osteoarthritis.

The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.

More about Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company focused on discovering, developing and delivering pharmaceutical therapies that improve patients’ health and quality of life. Its current lead program is iPPS, an injectable form of pentosan polysulfate sodium being developed for diseases driven by inflammation, with a primary focus on osteoarthritis, where its anti-inflammatory and tissue-regenerative properties are being advanced in Phase 3 trials.

Average Trading Volume: 1,258,863

Technical Sentiment Signal: Sell

Current Market Cap: A$101.6M

Learn more about PAR stock on TipRanks’ Stock Analysis page.